Tests Duobrii with biologic treatment in adults with psoriasis
Tests Duobrii for 12 weeks in adults with psoriasis already on biologic therapy.
Plain-language title generated from the registry record
Registry title: Duobrii in Combination With Biologics
Key facts
- Where
- East Windsor, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Psoriasis Treatment Center of Central New JerseyEast Windsor, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Psoriasis Treatment Center of Central New Jersey
- Trial code
- NCT04119102
- Record updated
- 30 April 2020
- Original description
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeksRead full original descriptionShow less
Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Inclusion: Male or female adult ≥ 18 years of age; Diagnosis of chronic plaque-type; Psoriasis affecting 2%-10% BSA; Patient is being treated with biologic therapy for a minimum of 24 weeks; Able and willing to give written informed consent prior to performance of any study-related procedures.
Exclusion: Patient not receiving a biologic agent, or receiving biologic agent <24weeks; Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit; Has previously used DUOBRII; Psoriasis affecting ˂2% or >10% BSA.